Peripheral blood markers of oxidative stress in Parkinson's disease

被引:75
作者
Younes-Mhenni, S.
Frih-Ayed, M.
Kerkeni, A.
Bost, M.
Chazot, G.
机构
[1] Univ Hosp Monastir, Dept Neurol, Monastir 5000, Tunisia
[2] Univ Monastir, Dept Biophys, Monastir, Tunisia
[3] UNESCO, Trace Element Inst, Lyon, France
[4] Hop Edouard Herriot, Biochem Federat, Trace Anal Lab, Lyon, France
关键词
Parkinson's disease; oxidative stress; superoxide dismutase; catalase; glutathione; malondialdehyde; SUPEROXIDE-DISMUTASE ACTIVITY; SUBSTANTIA-NIGRA; LIPID-PEROXIDATION; L-DOPA; ANTIOXIDANT ENZYMES; OXIDANT STRESS; GLUTATHIONE; BRAIN; ERYTHROCYTE; ABNORMALITIES;
D O I
10.1159/000103641
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oxidative stress and generation of reactive oxygen species are believed to be implicated in Parkinson's disease (PD). Erythrocyte activity of superoxide dismutase (SOD) and catalase, the blood glutathione system, and plasma levels of thiobarbituric-acid-reactive substances (TBARS) were measured in 80 PD patients. These biochemical parameters were also measured in 29 age-matched controls. Patients with PD had significantly higher red blood corpuscle (RBC) activity of SOD. The mean RBC activity of catalase in PD patients did not differ significantly from those of controls. RBC catalase activity was significantly lower in advanced cases of PD compared to early cases. Oxidized glutathione was significantly higher in RBCs of PD patients, although there were no changes in total glutathione and reduced glutathione compared to controls. TBARS content was increased in patients with PD. Levodopa therapy, age and duration of illness did not significantly influence the measured parameters. Our study supports the previous hypothesis that oxidative stress is implicated in the pathogenesis of PD. Perspectives for treatment of PD in the future could include antioxidant therapy. Copyright (C) 2007 S. Karger AG, Basel
引用
收藏
页码:78 / 83
页数:6
相关论文
共 49 条
  • [1] Abraham S, 2005, INDIAN J MED RES, V121, P111
  • [2] Plasma lipid peroxidation in sporadic Parkinson's disease.: Role of the L-dopa
    Agil, A
    Durán, R
    Barrero, F
    Morales, B
    Araúzo, M
    Alba, F
    Miranda, MT
    Prieto, I
    Ramírez, M
    Vives, F
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 240 (1-2) : 31 - 36
  • [3] NO EVIDENCE FOR SYSTEMIC OXIDANT STRESS IN PARKINSONS OR ALZHEIMERS-DISEASE
    AHLSKOG, JE
    UITTI, RJ
    LOW, PA
    TYCE, GM
    NICKANDER, KK
    PETERSEN, RC
    KOKMEN, E
    [J]. MOVEMENT DISORDERS, 1995, 10 (05) : 566 - 573
  • [4] Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease
    Ahlskog, JE
    Uitti, RJ
    Low, PA
    Tyce, GM
    OBrien, JF
    Nickander, KK
    [J]. NEUROLOGY, 1996, 46 (03) : 796 - 801
  • [5] Akerboom T P, 1981, Methods Enzymol, V77, P373
  • [6] BRAIN PEROXIDASE AND CATALASE IN PARKINSON DISEASE
    AMBANI, LM
    VANWOERT, MH
    MURPHY, S
    [J]. ARCHIVES OF NEUROLOGY, 1975, 32 (02) : 114 - 118
  • [7] BEERS RF, 1952, J BIOL CHEM, V195, P133
  • [8] Bostantjopoulou S, 1997, FUNCT NEUROL, V12, P63
  • [9] Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication
    Buhmann, C
    Arlt, S
    Kontush, A
    Möller-Bertram, T
    Sperber, S
    Oechsner, M
    Stuerenburg, HJ
    Beisiegel, U
    [J]. NEUROBIOLOGY OF DISEASE, 2004, 15 (01) : 160 - 170
  • [10] Cohen G, 1983, J Neural Transm Suppl, V19, P89